Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
  • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the invention relates to chromanone derivatives of the formula I.
• R 1 to R 4 are each independently of one another H, A, CN, Hai, OR 5 , COOR 5 ,
• Ar is unsubstituted or substituted by A, OR 5 , CN, shark, CF 3 , OCF 3 , NO 2 or N (R 5 ) 2, phenyl, shark F, Cl, Br or I, and their salts.
• the invention also relates to the optically active forms, the racemates, the enantiomers and the hydrates and solvates, e.g. Alcoholates, these compounds.
• the invention was based on the object of finding new compounds which can be used in particular as intermediates in the synthesis of medicaments.
• the invention relates to the chromanone derivatives of the formula I and their salts.
• A means alkyl, is linear or branched, and has 1 to 6, preferably 1, 2, 3, 4, 5 or 6 carbon atoms.
• A is preferably methyl, furthermore ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2 - or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-
• Methylpentyl 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1- Ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl.
• A is particularly preferably methyl.
• Acyl has 1 to 6, preferably 1, 2, 3 or 4 carbon atoms.
• Acyl means in particular acetyl, propionyl or butyryl.
• Ar means unsubstituted or mono-, di- or trisubstituted phenyl substituted by A, CF 3 , OR 5 , OCF 3 , CN, NO 2 , shark or N (R 5 ) 2 , where R 5 is H or A and A is one of the has previously given meanings.
• Ar is preferably phenyl.
• Shark is preferably F, Cl or Br.
• R 1 , R 2 , R 3 and R 4 are each independently H, A, CN, Hai, OR 5 , COOR 5 , CF 3 , OCF 3 , NO 2 , Ar, OAr, N (R 5 ) 2 or CON (R 5 ) 2 , where A, Hai, Ar and R 5 has one of the meanings described above.
• R 1 is preferably H.
• Particularly preferred is R 2 H.
• R 3 is preferably H.
• R 4 is preferably H.
• R 6 means acyl with 1 to 6 carbon atoms, -CO-Ar or an amino protecting group, wherein acyl and Ar are one of the previously specified
• R 6 is particularly preferably acyl.
• amino protecting group is generally known and refers to groups which are suitable for protecting (blocking) an amino group against chemical reactions. Unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups are particularly typical of such groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their type and size is otherwise not critical; however, preference is given to those having 1-20, in particular 1-8, carbon atoms.
• acyl group is to be understood in the broadest sense in connection with the present process.
• acyl groups derived from aliphatic, araliphatic, alicyclic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and in particular alkoxycarbonyl, alkenyloxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups.
• acyl groups are alkanoyl such as acetyl, propionyl, butyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as phenoxyacetyl; Alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl; Alkenyloxycarbonyl such as allyloxycarbonyl (aloe), aralkyloxycarbonyl such as CBZ (synonymous with Z), 4-methoxybenzyloxycarbonyl (MOZ), 4-nitrobenzyloxycarbonyl or 9-fluorenylmethoxycarbonyl (Fmoc); 2- (phenylsulfonyl) ethoxycarbonyl; Trimethylsilylethoxycarbonyl (Teo
• Preferred amino protecting groups are BOC, Fmoc and aloe, furthermore CBZ, benzyl and acetyl. Particularly preferred protective groups are BOC and Fmoc.
• the compounds of the formula I can have one or more chiral centers and therefore exist in various stereoisomeric forms. Formula I encompasses all of these forms.
• Particularly preferred compounds of the formula I are a) 2-aminomethyl-4-chromanone, b) (R) -2-aminomethyl-4-chromanone, c) (S) -2-aminomethyl-4-chromanone, and their salts.
• the invention further relates to a process for the preparation of chromanone derivatives of the formula I as claimed in claim 1 and of their salts, characterized in that a compound of the formula II
• R 1 , R 2 , R 3 , R 4 have the meanings given in claim 1 and
• R 6 is acyl having 1 to 6 carbon atoms, -CO-Ar or an amino protecting group, means, with the aid of a non-racemic chiral catalyst, to give a compound of the formula III
• R 1 to R 6 have a meaning given above, hydrogenated, and split off the rest of R 6 .
• (2-acetylaminomethyl) -chromen-4-one with various non-racemic chiral rhodium-diphosphane complexes can be hydrogenated to give enantiomerically enriched (2-acetylaminomethyl) -chroman-4-one and the acetyl group can be split off while avoiding racemization.
• the invention also relates to a process for the preparation of chromanone derivatives of the formula I, characterized in that the non-racemic chiral catalyst is a transition metal complex.
• the catalyst is particularly preferably a transition metal complex containing a metal selected from the group consisting of rhodium, iridium, ruthenium and palladium.
• the invention further relates to a process for the preparation of chromanone derivatives of the formula I, characterized in that the catalyst is a transition metal complex in which the transition metal is complexed with a chiral diphosphine ligand.
• the (R) - or (S) -enantiomer of the ligand in the catalyst is obtained in excess.
• Rh (COD) 2 OTf rhodium-cyclooctadiene triflate
• [Rh (COD) CI] 2 Rh (COD) 2 BF 4
• [lr (COD) CI] 2 serve as precursors for the chiral ligands, lr (COD) 2 BF 4 or [Ru (COD) CI 2 ] x .
• the compounds of the formula I and also the starting materials for their preparation are otherwise prepared by chemical reactions known per se, as described in the literature (for example in the standard works such as Houben-Weyl, Methods of Organic Chemistry, Georg-Thieme-Verlag, Stuttgart ) are described, namely under reaction conditions which are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in detail.
• the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
• Suitable inert solvents are, for example, Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide,
• reaction time of the enantioselective hydrogenation is between a few minutes and 14 days depending on the conditions used
• Reaction temperature between 0 and 150 °, usually between 20 and 130 °.
• the catalyst / substrate ratio is usually between 1: 100000 and 1:10, particularly preferably between 1: 10000 and 1: 100.
• the response time is then e.g. between 3 and 20 hours.
• the hydrogenation is carried out under 1-
• the radical R 6 where R 6 is acyl, is cleaved free of racemization, for example using NaOH or KOH in water, water-THF, water-dioxane or aqueous hydrochloric acid at temperatures between 0 and 100 °.
• a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
• acids are particularly suitable, the physiologically harmless ones Deliver salts.
• inorganic acids can be used, for example sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or poly-based carbon, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid, ethanedisulfonic acid, 2- Hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluene
• compounds of formula I with bases can be converted into the corresponding metal, in particular alkali metal or alkaline earth metal, or into the corresponding ammonium salts.
• the invention furthermore relates to the use of the compounds of the formula I as intermediates for the synthesis of medicaments.
• Corresponding drugs which preferably have effects on the central nervous system, are described, for example, in EP 0 707 007.
• the invention relates in particular to the use of the compounds of the formula I according to claim 1 in the synthesis of
• R 1 , R 2 , R 3 and R 4 are H and R 6 has the meaning given in claim 4, using a non-racemic chiral catalyst to give a compound of formula III
• R 1 to R 6 have a meaning given above, hydrogenated that b) from the thus obtained enantiomerically enriched mixture of the (R) and (S) compounds of formula III, wherein R 1 to R 6 have a meaning given above , the enantiomerically pure (R) compound of
• R 1 , R 2 , R 3 and R 4 are H, or a salt of this compound, is split off by d) the enantiomerically pure (R) compound of the formula I, in which R 1 to R 4 are H, as usual (R) -Aminomethyl-chroman is reduced by e) converting the (R) - (chroman-2-ylmethyl) amine thus obtained into its acid addition salt and converting it in a known manner to (R) -2- [5- (4 -Fluorophenyl) -3-pyridylmethylaminomethyl] -chroman and optionally converted into its acid addition salt, the (R) -enantiomer being obtained by crystallization from the entantiomerically enriched (R, S) mixture also after stage c) or after stage d) can be.
• the invention further relates to the use of the compounds of the formula I as intermediates for the synthesis of medicaments which have effects on the central nervous system.
• the reduction of the carbonyl group of the compounds of the formula I according to the invention for the preparation of the corresponding chroman derivatives of the formula I can be carried out by a Wolff-Kishner reduction (for example Paradkar, MV et al, in J. Chem. Res., Synop. 1998, 6, 318- 319) under conventional reaction conditions or by noble metal-catalyzed hydrogenation (e.g. PN Rylander, Hydrogenation Methods, Best Synthetic Methods, Academic Press 1985) under normal reaction conditions.
• a Wolff-Kishner reduction for example Paradkar, MV et al, in J. Chem. Res., Synop. 1998, 6, 318- 319
• noble metal-catalyzed hydrogenation e.g. PN Rylander, Hydrogenation Methods, Best Synthetic Methods, Academic Press 1985
• the noble metal catalysis for example with Pd on carbon (50% water-moist)
• the carbonyl group to the hydroxy group to the compound N- (4-hydroxy-chroman -2-ylmethyl) -acetamide 2 hydrogenated.
• the spin-off of the Acetyl group is carried out with a base, for example sodium hydroxide.
• the acid addition salt 3 of 2-aminomethyl-chroman-4-ol is obtained by adding an acid.
• Another noble metal-catalyzed hydrogenation is generated by the acid addition salt 4 of 2-aminomethyl-chroman.
• the invention therefore also relates to the compounds a) N- (4-hydroxy-chroman-2-ylmethyl) acetamide,) 2-aminomethyl-chroman-4-ol, c) (R) -N- (4-hydroxy- chroman-2-ylmethyl) -acetamide, d) (R) -2-aminomethyl-chroman-4-ol, e) (S) -N- (4-hydroxy-chroman-2-ylmethyl) -acetamide and f) ( S) -2-aminomethyl-chroman-4-ol.
• the invention further relates to the use of the compounds a) to f) described above in the synthesis of (R) -2- [5- (4-fluorophenyl) -3-pyridylmethylaminomethyl] -chroman and its salts.
• Salts enantiomerically pure or also racemic in a one-pot process directly by amide cleavage and subsequent reduction from N- (4-oxochroman-2-ylmethyl) acetamide.
• customary work-up means: if necessary, water is added, if necessary, depending on the constitution of the end product, the pH is adjusted to between 2 and 10, extracted with ethyl acetate or dichloromethane, and the mixture is separated off, dries the organic phase over sodium sulfate, evaporates and purifies by chromatography on silica gel and / or by crystallization. Rf values on silica gel.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pyrane Compounds (AREA)
• Pyridine Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7655302

Family Applications (1)

Country Status (19)

Families Citing this family (12)

Family Cites Families (5)

• 2000
  • 2000-09-07 DE DE10044091A patent/DE10044091A1/de not_active Withdrawn
• 2001
  • 2001-08-28 RU RU2003108856/04A patent/RU2273638C2/ru not_active IP Right Cessation
  • 2001-08-28 HU HU0302065A patent/HUP0302065A3/hu unknown
  • 2001-08-28 WO PCT/EP2001/009900 patent/WO2002020507A1/de not_active Application Discontinuation
  • 2001-08-28 CA CA002421287A patent/CA2421287A1/en not_active Abandoned
  • 2001-08-28 SK SK333-2003A patent/SK3332003A3/sk unknown
  • 2001-08-28 US US10/363,774 patent/US6812353B2/en not_active Expired - Fee Related
  • 2001-08-28 AU AU2001284039A patent/AU2001284039A1/en not_active Abandoned
  • 2001-08-28 BR BR0113584-8A patent/BR0113584A/pt not_active IP Right Cessation
  • 2001-08-28 CN CNB018150616A patent/CN1249044C/zh not_active Expired - Fee Related
  • 2001-08-28 JP JP2002525128A patent/JP2004508363A/ja active Pending
  • 2001-08-28 PL PL01362761A patent/PL362761A1/xx unknown
  • 2001-08-28 EP EP01962976A patent/EP1317438A1/de not_active Ceased
  • 2001-08-28 KR KR10-2003-7002303A patent/KR20030040402A/ko not_active Application Discontinuation
  • 2001-08-28 UA UA2003042933A patent/UA75892C2/uk unknown
  • 2001-09-03 MY MYPI20014131 patent/MY133893A/en unknown
  • 2001-09-07 AR ARP010104249A patent/AR030625A1/es not_active Application Discontinuation
• 2003
  • 2003-03-06 NO NO20031034A patent/NO20031034D0/no not_active Application Discontinuation
  • 2003-04-03 ZA ZA200302632A patent/ZA200302632B/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events